A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 198
- Registration Number
- NCT04951622
- Locations
- πΊπΈ
Neuromuscular Research Center and Clinic, Paradise Valley, Arizona, United States
πΊπΈHonorHealth Neurology, Scottsdale, Arizona, United States
πΊπΈUniversity of Southern California, Los Angeles, California, United States
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 31
- Registration Number
- NCT04951609
- Locations
- πΊπΈ
CincyScience, West Chester, Ohio, United States
πΊπΈSouthwest Autism Research and Resource Center, Phoenix, Arizona, United States
πΊπΈYale University, New Haven, Connecticut, United States
A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Other: Bronchoscopic BiopsyOther: Blood Sample
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 33
- Registration Number
- NCT04951154
- Locations
- πΊπΈ
Medstar Washington Hospital Center, Washington, District of Columbia, United States
πΊπΈRoswell Park Comprehensive Cancer Center, Buffalo, New York, United States
Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis
- Conditions
- Adenomatous Polyposis Coli
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT04948398
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
- Conditions
- Arthritis, Psoriatic
- Interventions
- Drug: GuselkumabDrug: Placebo
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 453
- Registration Number
- NCT04936308
- Locations
- π΅π±
Rheuma Medicus Sp z o o, Warszawa, Poland
π΅π±WroMedica I Bielicka A Strzalkowska s c, Wroclaw, Poland
πΊπΈRheumatology Associates, Birmingham, Alabama, United States
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 405
- Registration Number
- NCT04929210
- Locations
- πΊπΈ
Rheumatology Center of San Diego, San Diego, California, United States
π¬πͺLtd Health Center, Batumi, Georgia
π΅π±Twoja Przychodnia PCM, Poznan, Poland
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 650
- Registration Number
- NCT04923893
- Locations
- π¦π·
Hospital Privado Universitario De Cordoba, Cordoba, Argentina
π΅π±Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut BadawczyOddz w Gliwicach, Gliwice, Poland
π΅π±Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli, Lublin, Poland
A Study of JNJ-69095897 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: JNJ-69095897Other: Placebo
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT04920578
- Locations
- π³π±
Centre for Human Drug Research, Leiden, Netherlands
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- Drug: TAR-200Biological: Cetrelimab
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 163
- Registration Number
- NCT04919512
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈUrological Associates of Southern Arizona, P.C., Tucson, Arizona, United States
πΊπΈUAMS Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas, United States
A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 327
- Registration Number
- NCT04914429
- Locations
- π¨π³
Beijing Tongren Hospital, CMU, Beijing, China
π¨π³Xiangya Hospital Central South University, Changsha, China
π¨π³Shanghai Ruijin Hospital, Shanghai, China